North America Eliquis Market Size & Outlook, 2025-2033
The eliquis market in North America is expected to reach a projected revenue of US$ 6,259.1 million by 2033. A compound annual growth rate of -2% is expected of North America eliquis market from 2025 to 2033.
In terms of revenue, North America region accounted for 32.6% of the global eliquis market in 2024.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 5,019.3 million by 2033.
North America Eliquis (apixaban) market held the largest share of 32.56% in 2024, due to the high prevalence of atrial fibrillation and widespread clinical adoption of DOACs: advanced diagnostic capabilities and robust healthcare infrastructure support early identification and long-term management of thromboembolic disorders.
Eliquis benefits from favorable positioning in treatment guidelines and strong trust among cardiologists. Ongoing clinical trials and post-marketing surveillance continue to reinforce its safety and efficacy.
High prescription rates are also driven by growing awareness among aging populations. Strategic partnerships and effective distribution channels further strengthen its market hold across the region.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Eliquis Market Outlook will help companies and investors design strategic landscapes.
Atrial Fibrillation (Af) was the largest segment with a revenue share of 66.89% in 2024.
Horizon Databook has segmented the North America eliquis market based on atrial fibrillation (af), deep vein thrombosis (dvt), pulmonary embolism (pe), post-operative vte prophylaxis (at-risk cases) covering the revenue growth of each sub-segment from 2021 to 2033.
North America Eliquis (apixaban) market held the largest share of 32.56% in 2024, due to the high prevalence of atrial fibrillation and widespread clinical adoption of DOACs: advanced diagnostic capabilities and robust healthcare infrastructure support early identification and long-term management of thromboembolic disorders.
Eliquis benefits from favorable positioning in treatment guidelines and strong trust among cardiologists. Ongoing clinical trials and post-marketing surveillance continue to reinforce its safety and efficacy.
High prescription rates are also driven by growing awareness among aging populations. Strategic partnerships and effective distribution channels further strengthen its market hold across the region.
North America Eliquis Market Indication Outlook (Revenue, USD Million , 2021-2033)
Atrial Fibrillation (AF)
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Post-Operative VTE Prophylaxis (at-risk cases)
Others
North America Eliquis Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Reasons to subscribe to Eliquis Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Eliquis Market Outlook databook
Our clientele includes a mix of Eliquis Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Eliquis Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Eliquis Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.